Portfolio Holdings Detail for ISIN IE00BYZK4776
Stock Name / Fund iShares Healthcare Innovation UCITS ETF USD (Acc)
Issuer Blackrock
Entity holding fund iShares IV Public Limited Company
Entity Type Umbrella investment company with variable capital and having segregated liability between its funds
Entity LEI 549300ZP07LMR36K1T02
ETF Ticker DRDR(GBX) LSE
ETF Ticker 2B78(EUR) F
ETF Ticker 2B78.DE(EUR) CXE
ETF Ticker DRDR.LS(GBX) CXE
ETF Ticker HEAL.AS(EUR) CXE
ETF Ticker HEAL.LS(USD) CXE
ETF Ticker HEALz(USD) CXE
ETF Ticker HEAL(EUR) ETF Plus
ETF Ticker DRDR.L(GBP) LSE

Holdings detail for FDMT

Stock Name	4D Molecular Therapeutics Inc
Ticker	FDMT(USD) NASDAQ
TYPE	Common Stock
Country	USA
ISIN	US35104E1001

Show aggregate FDMT holdings

News associated with FDMT

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Given Consensus Recommendation of “Moderate Buy” by Brokerages: 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT – Get Free Report) has been assigned an average rating of “Moderate Buy” from the eleven analysts that are covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and eight have assigned a buy recommendation to the company. […] - 2025-08-19 04:19:16
4D Molecular Therapeutics (NASDAQ:FDMT) Given Sell (D-) Rating at Weiss Ratings: Weiss Ratings reissued their sell (d-) rating on shares of 4D Molecular Therapeutics (NASDAQ:FDMT – Free Report) in a report released on Thursday,Weiss Ratings reports. Other equities research analysts have also recently issued research reports about the company. Roth Capital dropped their price target on 4D Molecular Therapeutics from $44.00 to $38.00 and set a […] - 2025-08-15 04:50:58
Roth Capital Issues Pessimistic Forecast for 4D Molecular Therapeutics (NASDAQ:FDMT) Stock Price: 4D Molecular Therapeutics (NASDAQ:FDMT – Get Free Report) had its price target cut by Roth Capital from $44.00 to $38.00 in a note issued to investors on Tuesday,Benzinga reports. The firm currently has a “buy” rating on the stock. Roth Capital’s target price points to a potential upside of 469.72% from the company’s current price. […] - 2025-08-14 03:14:54
Bank of New York Mellon Corp Trims Stock Position in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT): Bank of New York Mellon Corp reduced its stake in shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT – Free Report) by 7.6% during the first quarter, Holdings Channel reports. The firm owned 134,849 shares of the company’s stock after selling 11,092 shares during the quarter. Bank of New York Mellon Corp’s holdings in 4D Molecular […] - 2025-08-04 05:58:54
Pre-Market Most Active for Aug 1, 2025 : TSLL, NAMM, SQQQ, FDMT, NVDA, FIG, TLT, NVO, BAX, BBAI, NIO, JOBY: The NASDAQ 100 Pre-Market Indicator is down -196.46 to 23,021.66. The total Pre-Market volume is currently 178,283,434 shares traded.The following are the most active stocks for the pre-market session: Direxion Daily TSLA Bull 2X Shares (TSLL) is -0.09 at $10.59, with 15,969,442 - 2025-08-01 09:29:53
4D Molecular Therapeutics (NASDAQ:FDMT) Earns “Sell (D-)” Rating from Weiss Ratings: 4D Molecular Therapeutics (NASDAQ:FDMT – Get Free Report)‘s stock had its “sell (d-)” rating reissued by investment analysts at Weiss Ratings in a research note issued on Tuesday,Weiss Ratings reports. Several other research analysts have also recently issued reports on FDMT. Chardan Capital reaffirmed a “buy” rating and issued a $25.00 target price on shares […] - 2025-07-31 02:28:50
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Receives Average Rating of “Moderate Buy” from Brokerages: 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT – Get Free Report) has been assigned a consensus recommendation of “Moderate Buy” from the ten brokerages that are covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and seven have issued a buy recommendation on the company. […] - 2025-07-25 05:48:57
4D Molecular Therapeutics (NASDAQ:FDMT) Given Buy Rating at Chardan Capital: Chardan Capital reaffirmed their buy rating on shares of 4D Molecular Therapeutics (NASDAQ:FDMT – Free Report) in a report released on Thursday,Benzinga reports. They currently have a $25.00 price objective on the stock. A number of other research firms have also recently commented on FDMT. Barclays reduced their price target on shares of 4D Molecular […] - 2025-07-04 04:59:45
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Purchases 2,925 Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT): UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT – Free Report) by 7.1% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 44,324 shares of the company’s stock after […] - 2025-06-13 04:32:51
ProShare Advisors LLC Has $91,000 Holdings in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT): ProShare Advisors LLC boosted its position in shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT – Free Report) by 30.1% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 16,369 shares of the company’s stock after acquiring an additional 3,783 shares […] - 2025-06-04 04:58:50
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Shares Purchased by Two Sigma Advisers LP: Two Sigma Advisers LP raised its position in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT – Free Report) by 452.0% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 126,400 shares of the company’s stock after purchasing an additional 103,500 shares during the […] - 2025-06-03 06:04:53
4D Molecular Therapeutics (NASDAQ:FDMT) Receives Sell (E+) Rating from Weiss Ratings: 4D Molecular Therapeutics (NASDAQ:FDMT – Get Free Report)‘s stock had its “sell (e+)” rating reaffirmed by equities researchers at Weiss Ratings in a report released on Saturday,Weiss Ratings reports. A number of other equities research analysts have also recently commented on FDMT. The Goldman Sachs Group reduced their target price on shares of 4D Molecular […] - 2025-05-27 05:26:57
Millennium Management LLC Has $7.91 Million Position in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT): Millennium Management LLC lifted its stake in shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT – Free Report) by 1,607.1% during the 4th quarter, HoldingsChannel reports. The firm owned 1,420,723 shares of the company’s stock after acquiring an additional 1,337,497 shares during the period. Millennium Management LLC’s holdings in 4D Molecular Therapeutics were worth $7,913,000 at […] - 2025-05-27 04:49:00
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Stock Holdings Lifted by Hsbc Holdings PLC: Hsbc Holdings PLC lifted its holdings in shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT – Free Report) by 88.3% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 34,413 shares of the company’s stock after buying an additional 16,142 shares during the […] - 2025-05-12 05:30:48
The Goldman Sachs Group Cuts 4D Molecular Therapeutics (NASDAQ:FDMT) Price Target to $44.00: 4D Molecular Therapeutics (NASDAQ:FDMT – Free Report) had its price objective trimmed by The Goldman Sachs Group from $51.00 to $44.00 in a research note published on Friday,Benzinga reports. The brokerage currently has a buy rating on the stock. A number of other analysts also recently weighed in on the stock. HC Wainwright reissued a […] - 2025-05-12 02:58:50
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Receives $26.71 Consensus Target Price from Brokerages: 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT – Get Free Report) has been given an average recommendation of “Moderate Buy” by the ten ratings firms that are presently covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and seven have assigned a buy […] - 2025-05-11 05:40:59
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Shares Acquired by MetLife Investment Management LLC: MetLife Investment Management LLC increased its position in shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT – Free Report) by 21.7% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 35,395 shares of the company’s stock after acquiring an additional 6,312 […] - 2025-05-09 05:20:52
Marshall Wace LLP Decreases Stake in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT): Marshall Wace LLP lessened its stake in shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT – Free Report) by 68.1% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 52,744 shares of the company’s stock after selling 112,449 shares during the quarter. Marshall Wace […] - 2025-05-05 05:02:59
Norges Bank Purchases Shares of 500,823 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT): Norges Bank acquired a new position in shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT – Free Report) during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 500,823 shares of the company’s stock, valued at approximately $2,790,000. Norges Bank owned approximately 1.08% of 4D Molecular Therapeutics at the […] - 2025-04-11 05:14:55
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Receives Consensus Recommendation of “Moderate Buy” from Analysts: Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT – Get Free Report) have been given an average rating of “Moderate Buy” by the nine brokerages that are currently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, two have given a hold recommendation and six have given a buy […] - 2025-04-11 04:32:50
Mitsubishi UFJ Asset Management Co. Ltd. Purchases 17,576 Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT): Mitsubishi UFJ Asset Management Co. Ltd. lifted its holdings in shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT – Free Report) by 168.0% in the fourth quarter, HoldingsChannel.com reports. The fund owned 28,041 shares of the company’s stock after acquiring an additional 17,576 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd.’s holdings in 4D […] - 2025-04-04 05:12:57
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Shares Sold by Intech Investment Management LLC: Intech Investment Management LLC reduced its position in shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT – Free Report) by 11.8% during the 4th quarter, HoldingsChannel reports. The fund owned 21,834 shares of the company’s stock after selling 2,927 shares during the period. Intech Investment Management LLC’s holdings in 4D Molecular Therapeutics were worth $122,000 at […] - 2025-03-28 05:56:53
4D Molecular Therapeutics (NASDAQ:FDMT) Receives Sell (E+) Rating from Weiss Ratings: Weiss Ratings reiterated their sell (e+) rating on shares of 4D Molecular Therapeutics (NASDAQ:FDMT – Free Report) in a research report sent to investors on Saturday,Weiss Ratings reports. FDMT has been the subject of several other research reports. Royal Bank of Canada lowered their target price on shares of 4D Molecular Therapeutics from $39.00 to […] - 2025-03-24 04:50:44
AlphaQuest LLC Purchases 14,441 Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT): AlphaQuest LLC lifted its position in shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT – Free Report) by 3,665.2% during the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 14,835 shares of the company’s stock after purchasing an additional 14,441 shares during the quarter. AlphaQuest LLC’s holdings in 4D Molecular Therapeutics were worth $83,000 at the […] - 2025-03-20 06:16:50
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Sees Significant Decrease in Short Interest: 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT – Get Free Report) was the target of a significant decline in short interest in the month of February. As of February 28th, there was short interest totalling 5,240,000 shares, a decline of 15.1% from the February 13th total of 6,170,000 shares. Approximately 12.2% of the shares of the company […] - 2025-03-20 05:42:55
Daiwa Securities Group Inc. Has $55,000 Stock Position in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT): Daiwa Securities Group Inc. grew its stake in shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT – Free Report) by 5,291.8% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 9,921 shares of the company’s stock after purchasing an additional 9,737 shares during the […] - 2025-03-18 05:42:56
Proficio Capital Partners LLC Buys 10,000 Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT): Proficio Capital Partners LLC boosted its stake in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT – Free Report) by 100.0% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 20,000 shares of the company’s stock after buying an additional 10,000 shares during the period. Proficio Capital Partners […] - 2025-03-13 05:09:05
4D Molecular Therapeutics (NASDAQ:FDMT) Given New $40.00 Price Target at Bank of America: 4D Molecular Therapeutics (NASDAQ:FDMT – Get Free Report) had its price target dropped by stock analysts at Bank of America from $42.00 to $40.00 in a research report issued on Monday,Benzinga reports. The firm currently has a “buy” rating on the stock. A number of other brokerages also recently commented on FDMT. Leerink Partners decreased […] - 2025-03-12 04:00:49
Financial Contrast: 4D Molecular Therapeutics (NASDAQ:FDMT) and Moderna (NASDAQ:MRNA): 4D Molecular Therapeutics (NASDAQ:FDMT – Get Free Report) and Moderna (NASDAQ:MRNA – Get Free Report) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, profitability, risk, earnings, valuation and institutional ownership. Valuation & Earnings This table compares 4D Molecular […] - 2025-03-06 06:37:55
Chardan Capital Issues Pessimistic Forecast for 4D Molecular Therapeutics (NASDAQ:FDMT) Stock Price: 4D Molecular Therapeutics (NASDAQ:FDMT – Free Report) had its target price reduced by Chardan Capital from $30.00 to $28.00 in a research report released on Tuesday,Benzinga reports. They currently have a buy rating on the stock. Several other equities analysts have also issued reports on the stock. Royal Bank of Canada cut their price target […] - 2025-03-05 06:26:55

iShares Healthcare Innovation UCITS ETF USD (Acc) FDMT holdings

Date	Number of FDMT Shares Held	Base Market Value of FDMT Shares	Local Market Value of FDMT Shares	Change in FDMT Shares Held	Change in FDMT Base Value	Current Price per FDMT Share Held	Previous Price per FDMT Share Held

Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdings

Share Trades of FDMT by Blackrock for IE00BYZK4776

Show aggregate share trades of FDMT

Date Action Quantity Market High Market Low Likely Trade Price Likely Trade Value (Profit/Loss) Average Price previous trades
2025-06-11 SELL -231 4.360* 5.01 Profit of 1,156 on sale
2025-05-30 SELL -236 3.620* 5.07 Profit of 1,196 on sale
2025-05-21 BUY 234 3.550* 5.16
2025-05-14 SELL -1,398 3.130* 5.22 Profit of 7,298 on sale
2025-04-30 SELL -230 3.370* 5.41 Profit of 1,244 on sale
2025-04-28 SELL -232 3.340* 5.45 Profit of 1,265 on sale
2025-04-25 SELL -230 3.340* 5.47 Profit of 1,259 on sale
2025-04-11 SELL -1,434 2.630* 5.68 Profit of 8,150 on sale
2025-04-08 SELL -717 2.510* 5.79 Profit of 4,151 on sale
2025-04-07 SELL -478 2.650* 5.83 Profit of 2,785 on sale
2025-03-31 SELL -480 3.230* 5.96 Profit of 2,861 on sale
2025-03-21 SELL -466 3.920* 6.14 Profit of 2,860 on sale
2025-03-12 SELL -240 4.240* 6.35 Profit of 1,524 on sale
2025-02-28 SELL -240 4.530* 6.64 Profit of 1,594 on sale
2025-02-25 BUY 240 4.540* 6.75
2025-02-20 SELL -240 4.670* 6.86 Profit of 1,647 on sale
2025-02-19 BUY 480 4.730* 6.90
2025-02-18 BUY 240 4.850* 6.94
2024-12-30 SELL -456 5.300* 7.95 Profit of 3,625 on sale
2024-12-06 SELL -219 7.350* 8.02 Profit of 1,756 on sale
2024-12-04 SELL -220 7.140* 8.09 Profit of 1,780 on sale
2024-12-03 SELL -442 7.080* 8.13 Profit of 3,593 on sale
2024-11-21 SELL -231 7.990* 8.29 Profit of 1,914 on sale
2024-11-20 SELL -240 8.410* 8.28 Profit of 1,987 on sale
2024-11-19 SELL -240 8.670* 8.26 Profit of 1,982 on sale
2024-11-18 SELL -900 8.320* 8.25 Profit of 7,427 on sale
2024-11-12 SELL -225 7.870* 8.28 Profit of 1,863 on sale
2024-11-07 SELL -224 8.280* 8.29 Profit of 1,857 on sale
2024-11-05 SELL -448 8.390* 8.28 Profit of 3,707 on sale
2024-10-28 SELL -225 8.570* 8.34 Profit of 1,877 on sale
Market high and low price is on the date.

Date	Action	Quantity	Likely Trade Price	Average Price previous trades
2025-06-11	SELL	-231	4.360*	5.01 Profit of 1,156 on sale
2025-05-30	SELL	-236	3.620*	5.07 Profit of 1,196 on sale
2025-05-21	BUY	234	3.550*	5.16
2025-05-14	SELL	-1,398	3.130*	5.22 Profit of 7,298 on sale
2025-04-30	SELL	-230	3.370*	5.41 Profit of 1,244 on sale
2025-04-28	SELL	-232	3.340*	5.45 Profit of 1,265 on sale
2025-04-25	SELL	-230	3.340*	5.47 Profit of 1,259 on sale
2025-04-11	SELL	-1,434	2.630*	5.68 Profit of 8,150 on sale
2025-04-08	SELL	-717	2.510*	5.79 Profit of 4,151 on sale
2025-04-07	SELL	-478	2.650*	5.83 Profit of 2,785 on sale
2025-03-31	SELL	-480	3.230*	5.96 Profit of 2,861 on sale
2025-03-21	SELL	-466	3.920*	6.14 Profit of 2,860 on sale
2025-03-12	SELL	-240	4.240*	6.35 Profit of 1,524 on sale
2025-02-28	SELL	-240	4.530*	6.64 Profit of 1,594 on sale
2025-02-25	BUY	240	4.540*	6.75
2025-02-20	SELL	-240	4.670*	6.86 Profit of 1,647 on sale
2025-02-19	BUY	480	4.730*	6.90
2025-02-18	BUY	240	4.850*	6.94
2024-12-30	SELL	-456	5.300*	7.95 Profit of 3,625 on sale
2024-12-06	SELL	-219	7.350*	8.02 Profit of 1,756 on sale
2024-12-04	SELL	-220	7.140*	8.09 Profit of 1,780 on sale
2024-12-03	SELL	-442	7.080*	8.13 Profit of 3,593 on sale
2024-11-21	SELL	-231	7.990*	8.29 Profit of 1,914 on sale
2024-11-20	SELL	-240	8.410*	8.28 Profit of 1,987 on sale
2024-11-19	SELL	-240	8.670*	8.26 Profit of 1,982 on sale
2024-11-18	SELL	-900	8.320*	8.25 Profit of 7,427 on sale
2024-11-12	SELL	-225	7.870*	8.28 Profit of 1,863 on sale
2024-11-07	SELL	-224	8.280*	8.29 Profit of 1,857 on sale
2024-11-05	SELL	-448	8.390*	8.28 Profit of 3,707 on sale
2024-10-28	SELL	-225	8.570*	8.34 Profit of 1,877 on sale

* (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection

The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close

Shorting History of FDMT

Date	Shorted Volume	Short Exempt Volume	Total Shares Traded	% Shorted
2025-09-19	134,541	0	275,268	48.9%
2025-09-18	51,342	2,829	287,145	17.9%
2025-09-17	52,522	0	140,425	37.4%
2025-09-16	72,869	0	161,520	45.1%
2025-09-15	47,500	2	154,256	30.8%
2025-09-12	113,209	0	181,094	62.5%
2025-09-11	109,675	400	265,951	41.2%
2025-09-10	123,827	0	250,963	49.3%
2025-09-09	113,491	0	176,750	64.2%
2025-09-08	89,599	0	204,172	43.9%
2025-09-05	124,943	1,910	361,714	34.5%
2025-09-04	125,008	0	233,134	53.6%
2025-09-03	85,925	3	228,941	37.5%
2025-09-02	39,251	0	151,751	25.9%
2025-08-29	30,637	0	85,293	35.9%
2025-08-28	90,823	7,206	217,025	41.8%
2025-08-27	64,482	0	151,190	42.6%
2025-08-26	88,724	0	217,773	40.7%
2025-08-25	123,588	1,877	318,913	38.8%
2025-08-22	85,067	15,444	191,648	44.4%
2025-08-21	49,534	0	159,271	31.1%
2025-08-20	112,646	11,262	303,645	37.1%
2025-08-19	217,083	12,264	495,595	43.8%
2025-08-18	288,880	1,360	636,686	45.4%
2025-08-15	269,577	4,027	602,044	44.8%
2025-08-14	252,215	137	570,396	44.2%
2025-08-13	240,721	12,852	791,178	30.4%
2025-08-12	194,289	0	464,275	41.8%
2025-08-11	89,615	0	234,587	38.2%
2025-08-08	136,209	3,093	264,904	51.4%
2025-08-07	129,937	4,134	287,648	45.2%
2025-08-06	157,561	0	391,474	40.2%
2025-08-05	464,768	58,578	1,000,659	46.4%
2025-08-04	645,472	68,861	1,633,160	39.5%
2025-08-01	8,479,421	37,736	13,939,455	60.8%
2025-07-31	68,643	144	212,819	32.3%
2025-07-30	38,041	200	135,998	28.0%
2025-07-29	49,906	0	161,974	30.8%
2025-07-28	41,932	0	130,639	32.1%
2025-07-25	35,628	291	112,822	31.6%
2025-07-24	37,718	0	102,659	36.7%
2025-07-23	42,652	728	149,213	28.6%
2025-07-22	20,078	0	148,195	13.5%
2025-07-21	24,606	0	146,046	16.8%
2025-07-18	44,570	0	162,438	27.4%

The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.

Stock Name / Fund	iShares Healthcare Innovation UCITS ETF USD (Acc)
Issuer	Blackrock
Entity holding fund	iShares IV Public Limited Company
Entity Type	Umbrella investment company with variable capital and having segregated liability between its funds
Entity LEI	549300ZP07LMR36K1T02
ETF Ticker	DRDR(GBX) LSE
ETF Ticker	2B78(EUR) F
ETF Ticker	2B78.DE(EUR) CXE
ETF Ticker	DRDR.LS(GBX) CXE
ETF Ticker	HEAL.AS(EUR) CXE
ETF Ticker	HEAL.LS(USD) CXE
ETF Ticker	HEALz(USD) CXE
ETF Ticker	HEAL(EUR) ETF Plus
ETF Ticker	DRDR.L(GBP) LSE